This is also supported by the absence of altered levels of autophagic markers, LC3A/B-I and LC3A/B-II, following SRF231 treatment in primary CLL cells or Ri-1 lymphoma cells (Suppl. The gene discussed is MAP1LC3A; the disease is lymphoma.